← Eichor
Condition: Advanced Solid Tumors With Mapk Pathway Mutations Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Solid Tumors With Mapk Pathway Mutations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAP
Phase 1/Phase 2 · 14 location(s) · D3 Bio (Wuxi) Co., Ltd · NCT05886920PAS-004 in Patients With Advanced Solid Tumors
Phase 1 · 7 location(s) · Pasithea Therapeutics Corp. · NCT06299839GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results
Phase 1/Phase 2 · 1 location(s) · Suzhou Genhouse Bio Co., Ltd. · NCT06310382
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.